Market Intelligence, Clinical Progress, and High-Purity Reagents for Histamine Intolerance, Polyamine Metabolism Modulation, and Inflammatory Disorders.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ABP1/AOC1 (Diamine Oxidase) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | AOC1 (DAO) Full-Length Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation) with copper cofactor incorporation tested. |
View AOC1 Products |
| Gene Delivery | AOC1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines expressing secreted DAO. |
View AOC1 Products |
| Benchmark Ab | Anti-AOC1 (DAO) Reference Antibody Recombinant positive control for ELISA, WB, and activity neutralization. |
View AOC1 Products |
| Validator | AOC1 siRNA Set For knockdown verification and specificity controls. |
View AOC1 Products |
| Related Target: AOC2 (VAP-1) | Sister copper amine oxidase, key inflammation marker. | View AOC2 Products |
| Related Target: HRH1 | Primary downstream histamine receptor for counter-screening and phenotypic validation. | View HRH1 Products |
| Related Target: HDC | Histamine synthesis enzyme (histidine decarboxylase) for pathway counter-screen. | View HDC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining Catalytic Conformation | HEK293 Expressed (Native Glycosylation) preserves native tertiary structure and enzymatic function. |
| Copper Cofactor Dependent Activity | Theoretical MW verification, copper incorporation tested. Endotoxin <1EU/ug. |
| Histamine Substrate Specificity | High Purity (>95%) by SDS-PAGE. Sequence Verified for active site integrity. |
| Animal-Derived Contamination | Fully recombinant human proteins; removes porcine/animal cross-reactivity risks. |
| Lack of Controls | Sequence-verified benchmark antibodies included for reproducible IHC/WB/ELISA. |
| False Positives | Validated siRNA included for precise specificity and genetic knockdown verification. |
Live ABP1/AOC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for ABP1/AOC1 (Diamine Oxidase, DAO) is rapidly evolving. Historically reliant on porcine kidney extracts for dietary supplementation, the market is shifting toward high-purity recombinant human AOC1 to mitigate immunogenicity and batch-to-batch variability. Concurrently, emerging oncology research is targeting AOC1 to disrupt tumor-associated polyamine metabolism. The next wave of R&D is focused on engineered enzymes with enhanced gastric stability for oral delivery, as well as small molecule inhibitors for inflammatory bowel disease (IBD), mast cell activation syndrome (MCAS), and post-viral inflammatory complications. First-generation DAO enzyme replacement therapies (ERT) are reaching Phase II trials for histamine intolerance and IBD, with growing interest in combined approaches (e.g., DAO modulators + TNF-α antagonists).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Enzyme Therapy | Sciotec, Stada, Specialty Biotechs | Histamine Intolerance, DAO Deficiency, Migraine | Enzymatic Activity Assay (U/mg). Need high-purity active enzyme with copper cofactor. |
| Small Molecule Inhibitors | Academic/Oncology spin-offs, Inflammation-focused Pharma | Solid Tumors (Polyamine targeting), IBD, Allergic Colitis | Selectivity Assay (need sequence-verified WT proteins + cross-reactivity panel against AOC2/AOC3). |
| Gene Therapy / mRNA | Preclinical biotech | Chronic Spontaneous Urticaria, MCAS | Expression Validation (need benchmark Abs and ORF lentivirus). |
| Dietary/Biologic Adjuncts | Nutraceutical Developers | Migraine, MCAS | Stability Assays (need endotoxin-controlled protein for in vivo validation). |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors
- Enzymatic Activity & Affinity: DAO must maintain high catalytic efficiency (kcat/Km) for histamine. HEK293-expressed protein with native glycosylation and copper loading is essential.
- Delivery & Stability: Oral ERT requires gastric stability (enteric coating); systemic injection demands low immunogenicity and extended half-life (PEGylation or Fc fusion).
- Selectivity: Inhibitors must discriminate against AOC2 (VAP-1) and AOC3 (SSAO). TarMart offers homologous protein panels for cross-reactivity testing.
- Patient Stratification: Clinical mutations (e.g., Thr16Met encoded by rs10156191) affect enzyme activity. TarMart can supply recombinant mutant proteins for personalized medicine assays.
Recommended Assay Workflow
- Early Screening: Fluorometric enzymatic assay using active AOC1 protein (copper-loaded, >95% pure).
- Selectivity Validation: Cross-reactivity panel against AOC2, AOC3 (copper amine oxidase family).
- Cell-Based Functional Assay: Lentivirus-based overexpression in mast cells / HEK293 to measure histamine clearance.
- Stability & PK: Accelerated stability testing (37°C/40°C) and ADA detection using high-purity endotoxin-controlled antigen.
- Mutation Profiling: Use Thr16Met mutant for activity comparison in patient subgroups.
Related Target Recommendations
For comprehensive pathway modulation and counter-screening, consider these targets:
- AOC2 (VAP-1): Sister copper amine oxidase, key inflammation marker. Include in selectivity panel.
- AOC3 (SSAO): Vascular adhesion protein-2, for triple selectivity screening.
- HRH1: Histamine receptor H1, downstream signaling node. Combine with DAO for combination therapy evaluation.
- HDC: Histidine decarboxylase, synthesis enzyme. Use for turnover balance assays.
- HNMT: Intracellular histamine N-methyltransferase – complementary degradation pathway.